The ADONIS trial found that dronedarone significantly decreased the risk of a first recurrence of atrial fibrillation or flutter within the 12-month study period by 27.5% compared to placebo. The drug also displayed good cardiac tolerability with no cases of torsades de pointes.
A20, an enzyme that regulates the immune system's response to bacterial infections, prevents over-reactions of the immune system to blood infections known as sepsis. The research shows A20 also controls the immune reaction that can cause inflammatory bowel disease.
A worldwide survey of catheter ablation for atrial fibrillation found varying methods, effectiveness, and complications. The study reported a significant increase in procedures, but also noted major complications such as early deaths, strokes, and tamponade.
The EURIDIS trial demonstrated that dronedarone significantly lowers the risk of first recurrence of AF/AFL within the 12-month study period by 21.6% compared to placebo. Dronedarone proved effective for all recurrences of atrial fibrillation or flutter, including those that were symptomatic.
Rimonabant has been shown to improve body weight, waist circumference, lipid profiles, and glycemic control. Patients taking rimonabant 20mg/day lost an average of 8.6kg, while those on placebo gained 4.8kg.
A global study found that nine easily measurable factors predict the majority of heart attack risk, regardless of region or ethnic group. These factors include cigarette smoking, high blood pressure, and diabetes, which collectively predict over 90% of heart attack risk.
The final pooled analysis of SPORTIF III and V1,2 confirms ximelagatran's effectiveness in preventing strokes in patients with atrial fibrillation. Ximelagatran offers a safer alternative to warfarin without coagulation monitoring or dose titration, reducing the risk of stroke by 62%.
In a breakthrough study, researchers found that dendritic cells, a type of immune cell, can be co-opted by tumors to promote angiogenesis and tumor growth. The study suggests a new approach to fighting solid tumors by targeting the interaction between angiogenesis and the immune response.
The ACTION study found that adding nifedipine to existing treatments for stable angina reduces the need for hospital interventions by 13% and prevents heart attacks and strokes. Nifedipine also reduces hospitalizations for heart failure in patients with stable angina.
The ICTUS study found that early invasive and selective invasive strategies are equivalent treatment options for patients with nSTE-ACS and elevated cardiac troponin. The study showed higher myocardial infarction rates but fewer rehospitalizations in the early invasive group.
Patients with atrial fibrillation are at increased risk for stroke and clotting complications, yet a significant percentage do not receive recommended clot-preventing medications. Asymptomatic patients should instead receive simple rate controlling drugs like beta-blockers, digitalis or verapamil.